Effect ofBorrelia burgdorferiGenotype on the Sensitivity of C6 and 2‐Tier Testing in North American Patients with Culture‐Confirmed Lyme Disease
Open Access
- 1 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (7), 910-914
- https://doi.org/10.1086/591529
Abstract
Background. A potential concern with any serologic test to detect antibodies to Borrelia burgdorferi is whether the epitopes incorporated in the test provide sufficient cross-reactivity to detect infection with all of the pathogenic strains of the species. This is a particular concern for the C6 test, which is based on reactivity to a single peptide. Methods. C6 testing and 2-tier testing were performed on acute-phase serum samples obtained from >158 patients with erythema migrans for whom the genotype of the borrelial isolate was defined on the basis of an analysis of the 16S-23S ribosomal DNA spacer region and/or on the genetic variation of the outer surface protein C gene (ospC). The sonicated whole cell–based enzyme-linked immunosorbent assay, the immunoblots used in the 2-tier testing, and the C6 assay all used antigens from B. burgdorferi sensu stricto strain B31. Results. The sensitivity of C6 testing (69.5%) was greater than that of 2-tier testing (38.9%) (P<.001); the difference in sensitivity, however, was statistically significant only for patients infected with 2 of the 3 ribosomal spacer type–defined genotypes. The lower sensitivity of 2-tier testing was attributable to the low sensitivity of the immunoblot tests, rather than the first-tier enzyme-linked immunosorbent assay. There was also a trend for the sensitivity of 2-tier testing to vary according to the ospC genotype for the 14 genotypes represented in the study ( P=.07); this relationship was not observed with C6 testing. Conclusions. Lack of sensitivity of the C6 test because of strain diversity seems less likely to be a limitation of this serologic test, compared with 2-tier testing in North American patients with early Lyme disease.This publication has 34 references indexed in Scilit:
- Borrelia burgdorferi Sensu Stricto Is Clonal in Patients with Early Lyme BorreliosisApplied and Environmental Microbiology, 2008
- The role of VlsE antigenic variation in the Lyme disease spirochete: persistence through a mechanism that differs from other pathogensMolecular Microbiology, 2007
- Borrelia burgdorferi Spirochetes That Harbor Only a Portion of the lp28-1 Plasmid Elicit Antibody Responses Detectable with the C 6 Test for Lyme DiseaseClinical and Vaccine Immunology, 2007
- C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in SwedenEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Comparative Genome Hybridization Reveals Substantial Variation among Clinical Isolates of Borrelia burgdorferi Sensu Stricto with Different Pathogenic PropertiesJournal of Bacteriology, 2006
- Comparison of Western Immunoblotting and the C6 Lyme Antibody Test for Laboratory Detection of Lyme DiseaseClinical and Vaccine Immunology, 2004
- C-Terminal Invariable Domain of VlsE Is Immunodominant but Its Antigenicity Is Scarcely Conserved among Strains of Lyme Disease SpirochetesInfection and Immunity, 2001
- Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.JCI Insight, 1986
- BiometryBiometrics, 1982